{"text_format":"3","workbook":"xls","n_sheets":2,"sheets":["删减版","原文件"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"删减版","index":0,"n_rows":9,"n_cols":12,"rows_kept":9,"flags":["formulas_cached_only"]}
["产品名称","规格","转换系数","单位","生产企业","报名企业","批准文号","承诺拟供应价格（元）","申报类型","省级挂网记录","核验结果","备注"]
["环硅酸锆钠散","5g","6","盒","浙江皓格药业有限公司","时森海（杭州）医药科技有限公司","国药准字H20255115",163.08,"申报价格低于支付标准的国谈仿制药","[来源省份:江西省,来源年份:2025,采购价:163.08],[来源省份:天津市,来源年份:2025,采购价:163.08],[来源省份:江苏省,来源年份:2025,采购价:163.08]","通过","申报价格低于支付标准的国谈仿制药"]
["波哌达可基注射液","8.0×10^12vg(2ml)/瓶","1","瓶","上海勉亦生物科技有限公司","上海信致医药科技有限公司","国药准字S20250016",93000,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:辽宁省,来源年份:2025,采购价:93000.00],[来源省份:江苏省,来源年份:2025,采购价:93000.00],[来源省份:湖北省,来源年份:2025,采购价:93000.00],[来源省份:广东省,来源年份:2025,采购价:93000.00],[来源省份:重庆市,来源年份:2025,采购价:93000.00]","通过","1类治疗用生物制品"]
["依折麦布阿托伐他汀钙片(II)","每片含依折麦布10mg与阿托伐他汀钙20mg(以C₃₃H₃₅FN₂O₅计)","30","盒","成都倍特药业股份有限公司","成都倍特药业股份有限公司","国药准字H20255179",66,"申报价格低于支付标准的国谈仿制药","[来源省份:山东省,来源年份:2025,采购价:66.00],[来源省份:浙江省,来源年份:2025,采购价:66.00],[来源省份:天津市,来源年份:2025,采购价:66.00]","通过","申报价格低于支付标准的国谈仿制药"]
["环硅酸锆钠散","5g","11","盒","浙江皓格药业有限公司","时森海（杭州）医药科技有限公司","国药准字H20255115",298.98,"申报价格低于支付标准的国谈仿制药","[来源省份:江西省,来源年份:2025,采购价:298.98],[来源省份:天津市,来源年份:2025,采购价:298.98],[来源省份:浙江省,来源年份:2025,采购价:298.98]","通过","申报价格低于支付标准的国谈仿制药"]
["注射用苏维西塔单抗","50mg/瓶","1","瓶","江苏先声生物制药有限公司","江苏先声生物制药有限公司","国药准字S20250037",5680,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:贵州省,来源年份:2025,采购价:5680.00],[来源省份:江苏省,来源年份:2025,采购价:5680.00],[来源省份:海南省,来源年份:2025,采购价:5680.00],[来源省份:广西壮族自治区,来源年份:2025,采购价:5680.00],[来源省份:安徽省,来源年份:2025,采购价:5680.00]","通过","1类治疗用生物制品"]
["重组人白蛋白注射液(水稻)","10g/瓶(20%,50mL)","1","瓶","武汉禾元生物科技股份有限公司","武汉禾元生物科技股份有限公司","国药准字S20250039",890,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:辽宁省,来源年份:2025,采购价:890.00],[来源省份:江苏省,来源年份:2025,采购价:890.00],[来源省份:安徽省,来源年份:2025,采购价:890.00],[来源省份:广东省,来源年份:2025,采购价:890.00],[来源省份:湖北省,来源年份:2025,采购价:890.00]","通过","1类治疗用生物制品"]
["西格列汀二甲双胍缓释片","磷酸西格列汀50mg(按C16H15F6N5O计)与盐酸二甲双胍500mg","30","瓶","浙江昂利康制药股份有限公司","浙江昂利康制药股份有限公司","国药准字H20255065",99.6,"申报价格低于支付标准的国谈竞价药品","[来源省份:江苏省,来源年份:2025,采购价:99.60],[来源省份:浙江省,来源年份:2025,采购价:99.60],[来源省份:山东省,来源年份:2025,采购价:99.60]","通过","申报价格低于支付标准的国谈竞价药品"]
["达格列净二甲双胍缓释片(I)","每片含达格列净10mg(按C₂₁H₂₅ClO₆计)和盐酸二甲双胍1000mg","7","瓶","以岭万洲国际制药有限公司","南京方生和医药科技有限公司","国药准字H20253855",26.16,"申报价格低于支付标准的国谈仿制药","[来源省份:湖北省,来源年份:2025,采购价:26.16],[来源省份:浙江省,来源年份:2025,采购价:26.16],[来源省份:重庆市,来源年份:2025,采购价:26.16]","通过","申报价格低于支付标准的国谈仿制药"]

{"sheet":"原文件","index":1,"n_rows":9,"n_cols":15,"rows_kept":9,"flags":["formulas_cached_only"]}
["产品编码","药品统一编码","产品名称","剂型","规格","转换系数","单位","生产企业","报名企业","批准文号","承诺拟供应价格（元）","申报类型","省级挂网记录","核验结果","备注"]
[3116546,"XV03AEH113P001010484858","环硅酸锆钠散","散剂","5g","6","盒","浙江皓格药业有限公司","时森海（杭州）医药科技有限公司","国药准字H20255115",163.08,"申报价格低于支付标准的国谈仿制药","[来源省份:江西省,来源年份:2025,采购价:163.08],[来源省份:天津市,来源年份:2025,采购价:163.08],[来源省份:江苏省,来源年份:2025,采购价:163.08]","通过","申报价格低于支付标准的国谈仿制药"]
[3113707,"XB02BDB273B002010185418","波哌达可基注射液","注射剂","8.0×10^12vg(2ml)/瓶","1","瓶","上海勉亦生物科技有限公司","上海信致医药科技有限公司","国药准字S20250016",93000,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:辽宁省,来源年份:2025,采购价:93000.00],[来源省份:江苏省,来源年份:2025,采购价:93000.00],[来源省份:湖北省,来源年份:2025,采购价:93000.00],[来源省份:广东省,来源年份:2025,采购价:93000.00],[来源省份:重庆市,来源年份:2025,采购价:93000.00]","通过","1类治疗用生物制品"]
[3116493,"XC10BAY348A001010102013","依折麦布阿托伐他汀钙片(II)","片剂","每片含依折麦布10mg与阿托伐他汀钙20mg(以C₃₃H₃₅FN₂O₅计)","30","盒","成都倍特药业股份有限公司","成都倍特药业股份有限公司","国药准字H20255179",66,"申报价格低于支付标准的国谈仿制药","[来源省份:山东省,来源年份:2025,采购价:66.00],[来源省份:浙江省,来源年份:2025,采购价:66.00],[来源省份:天津市,来源年份:2025,采购价:66.00]","通过","申报价格低于支付标准的国谈仿制药"]
[3116477,"XV03AEH113P001010284858","环硅酸锆钠散","散剂","5g","11","盒","浙江皓格药业有限公司","时森海（杭州）医药科技有限公司","国药准字H20255115",298.98,"申报价格低于支付标准的国谈仿制药","[来源省份:江西省,来源年份:2025,采购价:298.98],[来源省份:天津市,来源年份:2025,采购价:298.98],[来源省份:浙江省,来源年份:2025,采购价:298.98]","通过","申报价格低于支付标准的国谈仿制药"]
[3116484,"XL01FGS310B001010183106","注射用苏维西塔单抗","注射剂","50mg/瓶","1","瓶","江苏先声生物制药有限公司","江苏先声生物制药有限公司","国药准字S20250037",5680,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:贵州省,来源年份:2025,采购价:5680.00],[来源省份:江苏省,来源年份:2025,采购价:5680.00],[来源省份:海南省,来源年份:2025,采购价:5680.00],[来源省份:广西壮族自治区,来源年份:2025,采购价:5680.00],[来源省份:安徽省,来源年份:2025,采购价:5680.00]","通过","1类治疗用生物制品"]
[3114715,"XB05AAC181B002010185447","重组人白蛋白注射液(水稻)","注射剂","10g/瓶(20%,50mL)","1","瓶","武汉禾元生物科技股份有限公司","武汉禾元生物科技股份有限公司","国药准字S20250039",890,"1类化学药品、治疗用生物制品，中药、天然药物,  5.1类化学药品","[来源省份:辽宁省,来源年份:2025,采购价:890.00],[来源省份:江苏省,来源年份:2025,采购价:890.00],[来源省份:安徽省,来源年份:2025,采购价:890.00],[来源省份:广东省,来源年份:2025,采购价:890.00],[来源省份:湖北省,来源年份:2025,采购价:890.00]","通过","1类治疗用生物制品"]
[3116415,"XA10BDX252A010010104606","西格列汀二甲双胍缓释片","片剂","磷酸西格列汀50mg(按C16H15F6N5O计)与盐酸二甲双胍500mg","30","瓶","浙江昂利康制药股份有限公司","浙江昂利康制药股份有限公司","国药准字H20255065",99.6,"申报价格低于支付标准的国谈竞价药品","[来源省份:江苏省,来源年份:2025,采购价:99.60],[来源省份:浙江省,来源年份:2025,采购价:99.60],[来源省份:山东省,来源年份:2025,采购价:99.60]","通过","申报价格低于支付标准的国谈竞价药品"]
[3115851,"XA10BDD366A010010283343","达格列净二甲双胍缓释片(I)","缓释片","每片含达格列净10mg(按C₂₁H₂₅ClO₆计)和盐酸二甲双胍1000mg","7","瓶","以岭万洲国际制药有限公司","南京方生和医药科技有限公司","国药准字H20253855",26.16,"申报价格低于支付标准的国谈仿制药","[来源省份:湖北省,来源年份:2025,采购价:26.16],[来源省份:浙江省,来源年份:2025,采购价:26.16],[来源省份:重庆市,来源年份:2025,采购价:26.16]","通过","申报价格低于支付标准的国谈仿制药"]